Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1310 in Small Cell Lung Cancer
NCT06179069Phase 1Recruiting
- Sponsor
- Zai Lab
- Start
- Jan 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label trial of zocilurtatug pelitecan in small cell lung cancer (SCLC) (13 arms), sponsored by Zai Lab. Primary endpoints: Dose Limiting Toxicities up to 24 months, Treatment Emergent Adverse Events up to 24 months and 4 more. Started Jan 2024; status: recruiting.
02
Drugs
zocilurtatug pelitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06179069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179069.